Navigation Links
Respironics, Inc. Issues Voluntary Recall of a Limited Number of Trilogy Ventilators

MURRYSVILLE, Pa., July 17, 2012 /PRNewswire/ -- Respironics, Inc. announced today that it is voluntarily recalling 80 Trilogy Model 100 and five Trilogy Model 202 ventilators in the United States. The recall was initiated on April 27, 2012 and is being conducted to replace a potentially defective electronic component. Respironics has received no reports from users of ventilator malfunction, injury or death related to this issue.

The Trilogy 100 ventilator provides volume and pressure support ventilation for adult and pediatric patients in both invasive and noninvasive home, institution/hospital, and portable applications. The Trilogy 202 is for hospital use and allows blending of external oxygen with volume and pressure support. The Trilogy 200 ventilator model distributed in the United States is not affected by this recall.

The defective component is in the power supply of the ventilators, and if it fails, there may be a reduction or cessation of ventilator therapy and/or the ventilator may fail to alarm and alert caregivers to this situation. Failure of a caregiver to respond to a failed device could result in harm to a ventilator dependent patient.

Respironics has notified all United States distributors, providers, sales personnel and customers that may have devices subject to this recall. Replacement units have been shipped to all affected customers. To date, all affected Trilogy 202 devices have been returned, and Respironics is working to arrange the return of the nine affected Trilogy 100 units that remain with customers. Customers with questions about this recall may contact Respironics Customer Service at 1-877-387-3311. 

Respironics has notified the U.S. Food & Drug Administration (FDA) of its decision to voluntarily recall the affected product. Any adverse reactions experienced with the use of this product should be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at Adverse reactions and/or quality problems should also be reported to Philips Respironics at 1-800-345-6443. 

SOURCE Respironics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Carl Icahn Issues Letter To Howard Solomon Of Forest Laboratories
2. MLB All-Star Pitcher CC Sabathia Issues Fast Relief Challenge to Generate Donations for the American Red Cross
3. PAREXEL International Issues Earnings Guidance In Conjunction With Investor Day
4. FDA Issues Complete Response Letter for 800mg PREZISTA® (darunavir) Tablet
5. OncoSec Medical Issues Letter to Shareholders
6. Ameritox Announces Educational Resources to Help Physicians Navigate Complex Compliance Issues
7. BD Issues 2011 Sustainability Report
8. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
9. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
10. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
Breaking Medicine News(10 mins):